Shanghai Allist Pharmaceuticals Co Ltd
SSE:688578

Watchlist Manager
Shanghai Allist Pharmaceuticals Co Ltd Logo
Shanghai Allist Pharmaceuticals Co Ltd
SSE:688578
Watchlist
Price: 96.85 CNY -1.75% Market Closed
Market Cap: ¥43.6B

Relative Value

The Relative Value of one Shanghai Allist Pharmaceuticals Co Ltd stock under the Base Case scenario is 91.11 CNY. Compared to the current market price of 96.85 CNY, Shanghai Allist Pharmaceuticals Co Ltd is Overvalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
91.11 CNY
Overvaluation 6%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Shanghai Allist Pharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shanghai Allist Pharmaceuticals Co Ltd
SSE:688578
43.6B CNY 9.2 22 18 18
US
Eli Lilly and Co
NYSE:LLY
948.8B USD 16 51.5 34.6 37.1
US
Johnson & Johnson
NYSE:JNJ
563B USD 6 21 14.6 17.9
CH
Roche Holding AG
SIX:ROG
286.3B CHF 4.7 30.4 12.8 15
UK
AstraZeneca PLC
LSE:AZN
213.6B GBP 5.1 31.5 15 22
US
Merck & Co Inc
NYSE:MRK
288.1B USD 4.5 15.1 10.7 12.7
CH
Novartis AG
SIX:NOVN
224.1B CHF 5.1 20 12.6 16.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.1 10.6
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
98.2B EUR 1.7 8.2 7.7 7.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Shanghai Allist Pharmaceuticals Co Ltd
SSE:688578
Average EV/EBITDA: 43.3
18
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.6
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
15
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
CH
Novartis AG
SIX:NOVN
12.6
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
1%
9.1
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1